Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

Table 1 Baseline characteristics of 27 patients with relapsed or refractory multiple myeloma (RRMM)

Characteristic	No. of patients (%)
Age^a (years)	56 (36–77)
Sex
Men	18 (66.7)
Women	9 (33.3)
ISS stage^b
I	6 (23.1)
II	14 (53.8)
III	6 (23.1)
Time since diagnosis^a (months)	21 (4–60)
Subtype of disease
IgG	11 (40.7)
IgA	6 (22.2)
IgD	5 (18.5)
Light chain	5 (18.5)
β2-microglobulin^b
Level^a (mg/L)	3.4 (1.1–16.7)
<3.5 mg/L	14 (53.8)
≥3.5 mg/L	12 (46.2)
Prior therapy
Number^a (cycles)	3 (1–8)
0–3 cycles	14 (51.9)
>3 cycles	13 (48.1)
Prior regimen
Glucocorticoids	25 (92.6)
Alkylating agents	23 (85.2)
IMiDs (thalidomide or lenalidomide)	21 (77.8)
Vincristine	19 (70.3)
Bortezomib	14 (51.9)
Both bortezomib and IMiDs	9 (33.3)
Autologous stem cell transplantation	5 (18.5)

ISS international staging system, IMiDs immunomodulatory drugs
^aThese values are presented as median followed by ranges in the parentheses; other values are presented as number of patients followed by percentages in the parentheses
^bBaseline β2-microglobulin was not determined in one patient; who could not be grouped into any ISS stage

ISSN: 2523-3548